ESR1 and endometrial cancer: In summary, most of the data support inhibitory AhR–ERα crosstalk, where the activation of the AhR inhibits ERα signaling, leading to the inhibition of breast and endometrial cancer cell proliferation, survival, migration/invasion, and metastasis.